Sugi Predict

Sugi Predict / Compounds / SCHEMBL19160486

SCHEMBL19160486

SCHEMBL19160486

Cn1cnnc1Sc1ncnc2cnccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 5/20 0.42
▸ PIP4K2C Q8TBX8 1/20 0.39
▸ HSD17B10 Q99714 4/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ CBLB Q13191 2/20 0.34
▸ EGFR P00533 2/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ NFATC1 O95644 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ HBB P68871 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19160372 0.90 GCK (0.44) GCKPIP4K2CHSD17B10KDM4EKDM1A
SCHEMBL19160413 0.81 KMT2A (0.38) GCKHSD17B10KDM4EKDM1AEGFR
SCHEMBL19160368 0.79 TSHR (0.52) PIP4K2CHSD17B10HTTSMN1; SMN2TSHR
SCHEMBL19160774 0.78 GCK (0.39) GCKPIP4K2CHSD17B10KDM4EKDM1A
SCHEMBL19160427 0.77 GCK (0.42) GCKPIP4K2CHSD17B10KDM4EKDM1A
SCHEMBL19160374 0.75 HSD17B10 (0.42) GCKPIP4K2CHSD17B10KDM4ECBLB
SCHEMBL19160451 0.75 PIP4K2C (0.41) GCKPIP4K2CHSD17B10KDM4ECBLB
SCHEMBL19160401 0.72 PIP4K2C (0.41) GCKPIP4K2CHSD17B10KDM4ECBLB
SCHEMBL19160378 0.72 GCK (0.47) GCKPIP4K2CHSD17B10KDM4EALDH1A1
SCHEMBL19160472 0.72 PIP4K2C (0.39) GCKPIP4K2CHSD17B10KDM4ECBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230558-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-01-25 — — US disclosed
US-11008341-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-05-18 — — US disclosed
US-10865214-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies The Trustees of Columbia University in they City of New York (US) 2020-12-15 — — US disclosed
US-20200216469-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES UNIV COLUMBIA (US) 2020-07-09 — — US disclosed
US-10626124-B2 — — 2020-04-21 — — US disclosed
US-20190112317-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES NY STATE PSYCHIATRIC INSTITUTE 2019-04-18 — — US disclosed
US-20170210759-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2017-07-27 — — US disclosed
US-20170210759-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190112317-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885
US-11008341-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885
US-10626124-B2 — MAPT, SQSTM1, TFEB GCK 1489/4885PIP4K2C 835/4885HSD17B10 2923/4885
US-11230558-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885
US-10865214-B2 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885
US-20200216469-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885
US-20170210759-A1 ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES MAPT, SQSTM1, ATG7 GCK 2387/4885PIP4K2C 173/4885HSD17B10 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.